Rate My Professor Camron Bryant

Bryant's research integrates rodent forward genetic crosses, multi-omics approaches, gene editing, AAV targeting, and behavioral neuroscience to identify the genetic and neurobiological factors underlying vulnerability to addiction, focusing on opioids and psychostimulants, as well as binge eating and pain. Notable discoveries include the RNA-binding protein hnRNP H as a quantitative trait gene for methamphetamine sensitivity (Yazdani et al., PLOS Genetics, 2015), Cyfip2 as a major genetic factor in binge eating (Kirkpatrick et al., Biological Psychiatry, 2017), and Zhx2 as a transcriptional repressor influencing oxymorphone metabolite brain concentration and oxycodone reward (Beierle et al., Journal of Pharmacology and Experimental Therapeutics, 2022). He pioneered near-isogenic reduced complexity crosses to facilitate analysis of complex traits (Bryant et al., Trends in Genetics, 2020). As principal investigator on major NIH grants, such as U01DA050243 on the genetic basis of oxycodone dependence (2020-2025) and U01DA055299 on systems genetics of cocaine traits (2022-2027), his work has advanced pharmacogenomic insights into substance use disorders. Bryant is a Full Member of the American College of Neuropsychopharmacology (elected 2021, Associate Member 2016), past-President of the International Behavioural and Neural Genetics Society, a standing member of the NIH BRLE study section (2021-2025), and serves on the editorial board of Genes, Brain and Behavior (2022-present). His honors include the IBANGS Outstanding Young Investigator Award for Postdocs (2008), Young Scientist Awards (2013, 2014), and multiple travel awards from ACNP, NIH/NIDA, and IBANGS.